Stocktoria
REVELATION BIOSCIENCES, INC. REVB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-08
REVELATION BIOSCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $4.1M | $3.5M | $4.1M | $5.4M | $6.9M |
| Operating income | -$9.1M | -$8.0M | -$8.7M | -$10.9M | -$12.0M |
| Interest expense | — | — | — | — | $41,759 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.9M | -$15.0M | -$120,254 | -$10.8M | -$12.0M |
| EPS (diluted) | $-23.95 | $-1052.16 | $-8.44 | $-149.20 | $-42.50 |
| Operating cash flow | -$8.3M | -$18.3M | -$7.3M | -$11.2M | -$11.1M |
| Free cash flow | — | -$18.3M | — | — | -$11.2M |
| Cash & equivalents | $10.7M | $6.5M | $12.0M | $5.3M | $1.3M |
| Total assets | $11.6M | $6.6M | $12.2M | $5.5M | $2.0M |
| Total liabilities | $2.7M | $1.9M | $5.6M | $4.5M | $2.1M |
| Shareholders' equity | $8.9M | $4.7M | $6.6M | $1.1M | -$7.8M |
Source: SEC EDGAR filings · CIK 0001810560 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.